Thursday, October 18, 2012

Anti-Rejection Drug May Also Prevent Cancer

The San Antonio Express News yesterday reported that a local immunologist and professor of medicine at The University of Texas Health Science Center here in San Antonio has recently been awarded a two-year, 450,000 dollar grant, from the National Cancer Institute to study the possible connection between a drug and cancer prevention.  The drug in question, Rapamycin, was first approved as an anti-rejection drug for transplant patients.  However, doctors have begun theorizing that the drug's known anti-aging properties could also possibly help boost the immune system's response to attacking and killing cancer cells as soon as they appear. 

To read more about the study click on the link below:

We apologize for the lapse in blog entries and hope that this finds everyone happy and healthy.


No comments:

Post a Comment